Trial Profile
A phase IIa, 28-day treatment, multi-center, randomized, comparator-controlled, observer-blind trial with intra-individual left/right comparison to investigate the anti-psoriatic efficacy and the safety of an LAS41004 formulation in comparison to an active reference in patients with mild to moderate plaque psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jun 2015
Price :
$35
*
At a glance
- Drugs Betamethasone dipropionate/bexarotene (Primary) ; Betamethasone-dipropionate/calcipotriol
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Almirall Hermal GmbH
- 15 Nov 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 13 May 2014 32646
- 13 May 2014 New trial record